RxDoctor Payments Data

Stephanie Coleman, MD

Internal Medicine · Waterford, MINPI 1528487246

Payments from drug & device makers

$313in general payments, 2019–2025

Across 15 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$72
  • BD$53
  • Blueprint Medicines Corporation$46
  • Bayer$24
  • Novo Nordisk$20
  • AbbVie$19
  • plus $79 from 5 others

What the payments were for

  • Speaking & faculty fees$5317%
  • Food & beverage$24478%
  • Education$155%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$313 in reported general payments places this provider in the 55th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$19,865
Medicare patients
94
Services billed
309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter97$96,622
EliquisApixaban60$68,089
OzempicSemaglutide56$57,164
TrulicityDulaglutide45$50,561
MounjaroTirzepatide34$36,925
FarxigaDapagliflozin Propanediol34$28,950
XareltoRivaroxaban19$21,245
JardianceEmpagliflozin24$19,404
MyrbetriqMirabegron17$18,481
LinzessLinaclotide13$15,808
TrintellixVortioxetine Hydrobromide18$8,411
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$8,013
Semglee (Yfgn) PenInsulin Glargine-Yfgn14$5,886
Albuterol Sulfate HfaAlbuterol Sulfate146$5,534
Breo ElliptaFluticasone/Vilanterol12$5,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$72$102,085109 claims
Lilly USA, LLCTrulicity, Mounjaro$14$87,48679 claims
PfizerEliquis, Premarin$17$70,55271 claims
Novo NordiskOzempic, Novolog$20$61,78273 claims
AstraZenecaFarxiga$15$28,95034 claims
Astellas Pharma US IncMyrbetriq$17$18,48117 claims
AbbVieLinzess, Synthroid$19$17,53835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Waterford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →